Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 3Phase NA 2Phase 3 1Phase 1 1

Status

Withdrawn 1Recruiting 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 23Recurrence 6Neoplasms 4Neoplasms, Plasma Cell 3Lymphoma, Non-Hodgkin 3Leukemia, Myeloid, Acute 3Immunoglobulin Light-chain Amyloidosis 3Hematologic Neoplasms 3Paraproteinemias 2Hematologic Diseases 2Corneal Diseases 2Carcinoma, Non-Small-Cell Lung 2Blood Protein Disorders 2Various Advanced Cancer 1Triple Negative Breast Neoplasms 1Proteostasis Deficiencies 1Pancreatic Neoplasms 1Neoplasm, Residual 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Hodgkin Disease 1Glioblastoma 1Amyloidosis 1

Interventions

Dexamethasone 7daratumumab 3Peripheral Blood Stem Cell Transplantation 3Calcium Dobesilate 3venetoclax 2pomalidomide 2ixazomib 2fludarabine phosphate 2Whole-Body Irradiation 2Mycophenolic Acid 2Lenalidomide 2Cyclosporine 2Cyclophosphamide 2ethanolamine oleate 1dexamethasone acetate 1carfilzomib 1birtamimab 1belantamab mafodotin 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Thalidomide 1Sulfamethoxazole 1Sodium Chloride 1Saline Solution, Hypertonic 1Saline Solution 1Phenytoin 1Pentetic Acid 1Methotrexate 1Melphalan 1In Situ Hybridization, Fluorescence 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Immunoglobulin Light-chain Amyloidosis × daratumumab × Clear all
NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Columbia University

Phase 1/2 Recruiting
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

NCT05486481 2025-03-06

Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)

University of California, San Francisco

Phase 1/2 Withdrawn
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT02841033 2021-05-07

Daratumumab for the Treatment of Patients With AL Amyloidosis

Boston Medical Center

Phase 1/2 Completed
22 enrolled 10 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡